RxDoctor Payments Data

Rikin Kadakia, MD

Interventional Cardiology · Salinas, CANPI 1154718526

Payments from drug & device makers

$238,386in general payments, 2019–2025

Across 662 payments — averaging $360.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$138K
  • Shockwave Medical, Inc$79K
  • Edwards Lifesciences$4K
  • Abbott$3K
  • Abiomed$2K
  • Medtronic$2K
  • plus $11K from 44 others

What the payments were for

  • Consulting fees$19,2828%
  • Speaking & faculty fees$158,13466%
  • Grants$2000%
  • Travel & lodging$31,88613%
  • Food & beverage$28,22012%
  • Education$4710%
  • Gifts$840%
  • Entertainment$1090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$238,386 in reported general payments places this provider in the 85th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$395,355
Medicare patients
1,190
Services billed
4,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$153,301
XareltoRivaroxaban19$29,405
OzempicSemaglutide12$10,257
Repatha SureclickEvolocumab11$7,108
Rosuvastatin Calcium173$3,480
Amiodarone Hcl46$1,898
Metoprolol Succinate164$1,834
ClopidogrelClopidogrel Bisulfate128$1,488
Bumetanide37$1,095
Atorvastatin Calcium135$1,064
Carvedilol102$639
Doxazosin Mesylate34$566
Losartan Potassium71$560
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide42$521
Ezetimibe13$521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$418$153,301138 claims
Johnson & JohnsonXarelto$25$29,40519 claims
Novo NordiskOzempic$137,856$10,25712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Salinas

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →